Kaken Pharmaceutical Co., Ltd. (TYO:4521)
4,786.00
-37.00 (-0.77%)
Mar 13, 2025, 3:30 PM JST
Kaken Pharmaceutical Revenue
Kaken Pharmaceutical had revenue of 24.62B JPY in the quarter ending December 31, 2024, with 32.97% growth. This brings the company's revenue in the last twelve months to 93.35B, up 29.48% year-over-year. In the fiscal year ending March 31, 2024, Kaken Pharmaceutical had annual revenue of 72.04B, down -1.29%.
Revenue (ttm)
93.35B
Revenue Growth
+29.48%
P/S Ratio
1.94
Revenue / Employee
82.25M
Employees
1,135
Market Cap
180.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 72.04B | -940.00M | -1.29% |
Mar 31, 2023 | 72.98B | -3.05B | -4.01% |
Mar 31, 2022 | 76.03B | 1.06B | 1.41% |
Mar 31, 2021 | 74.98B | -14.25B | -15.97% |
Mar 31, 2020 | 89.23B | -4.93B | -5.24% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,170.61B |
Takeda Pharmaceutical Company | 4,579.02B |
Daiichi Sankyo Company | 1,795.99B |
HOYA Corporation | 837.44B |
Otsuka Holdings | 2,329.86B |
Terumo | 1,011.15B |
Astellas Pharma | 1,867.63B |
Olympus | 993.33B |
Kaken Pharmaceutical News
- 4 months ago - Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Benzinga